Neovacs and Lupus Europe Join Voices on World Lupus Day
May 10 2017 - 8:55AM
Neovacs (Alternext Paris:ALNEV), a leader in
active immunotherapies for the treatment of autoimmune diseases,
and
Lupus Europe, umbrella association of,
currently, 24 national lupus patient organisations from 22 member
countries throughout Europe, together join voices on the occasion
of World Lupus Day in order to raise awareness about this chronic
and debilitating autoimmune disease - whose origin is still poorly
understood by the general population, but also decision makers.
Lupus affects numerous organs and tissues,
producing heterogeneous clinical signs (skin rash, arthritis,
photosensitivity, renal damage, neurological disorders, anaemia…),
which vary from one person to another and change as the disease
progresses, with periods of remissions and relapses or flares.
Lupus affects mostly women (9 women for every 1 man). All over
Europe, up to 500,000 people are affected with different grades of
severity.1
Fortunately, they can count on patient
associations to accompany them on their path with the disease.
Lupus Europe gathers those organisations in order
to better support people living with lupus all around Europe, help
them understand their condition, and better improve research and
scientific knowledge of the disease.
One of these scientific actors,
Neovacs, is a specialist in active immunotherapy,
dedicated to developing therapeutic vaccines for the treatment of
autoimmune diseases such as lupus. Unlike monoclonal antibodies
used in many cancer treatments and inflammatory diseases
treatments, Kinoid® therapeutic vaccines developed by
Neovacs induce the patients’ immune system to
produce their own polyclonal antibodies. Recent research
highlighted the major role of IFNɑ in the immune system dysfunction
associated with lupus, opening new perspectives for the treatment
of this condition. IFNɑ Kinoid is the most advanced product
produced by Neovacs. This vaccine is currently in
phase IIb in lupus indication, which is hopeful for patients whose
participation in clinical trials is crucial to help scientists
discover new treatments.
“50 years ago, lupus meant a death sentence.
Today, people can have a relatively normal life, thanks to more -
but not yet enough - treatments and a better understanding of the
disease. It’s the clinical trials that are vital to lupus. In terms
of research, we are quite excited about a few labs who have taken
interest into lupus these past few years. We are watching with
great interest the possibility of a vaccination, which would be
magnificent for the patients,” explains Anne Charlet, Vice
Chair of the Lupus Europe association.
About NeovacsListed on
Alternext Paris since 2010, Neovacs is today a leading
biotechnology company focused on an active immunotherapy technology
platform (Kinoids) with applications in autoimmune and/or
inflammatory diseases. On the basis of the company’s proprietary
technology for inducing a polyclonal immune response (covered by
five patent families that potentially run until 2032) Neovacs is
focusing its clinical development efforts on IFNα-Kinoid, an
immunotherapy being developed for the indication of lupus and
dermatomyositis. Neovacs is also conducting preclinical development
works on other therapeutic vaccines in the fields of auto-immune
diseases, oncology, allergies and Type 1 diabetes. The goal of the
Kinoid approach is to enable patients to have access to safe
treatments with efficacy that is sustained in these life-long
diseases. www.neovacs.fr
About Lupus EuropeLUPUS EUROPE
is the umbrella association of currently 24 national lupus patient
organisations from 22 member countries throughout Europe. It is a
registered charity supporting people with lupus in Europe, keeping
member countries informed
by blog, Facebook, Twitter, and
regular NewsFlashes on the work of LUPUS EUROPE,
promoting lupus at conventions and meetings throughout Europe. Its
mission is to:
- make lupus a well-known illness throughout Europe and, in
partnership with the medical profession, secure high quality
standards of treatment and support for people with lupus, their
families and their care
- encourage and support the health and social systems of member
countries, to allow people with lupus to live independent lives and
be recognised as equal members of society.
http://lupus-europe.eu/
____________________________
1 Cervera R, Khamashta MA, Hughes GR. The Euro-lupus project:
epidemiology of systemic lupus erythematosus in Europe. Lupus 2009;
18: 869–74.Carter EE, Barr SG, Clarke AE. The global burden of SLE:
prevalence, health disparities and socioeconomic impact. Nature
reviews. Rheumatology 2016: 12(10): 605–620.
Contacts
NEOVACS – Corporate Communication & Investor Relations
Charlène Masson
+33 (0)1 53 10 93 14
cmasson@neovacs.com
NEWCAP – Press Relations
Annie-Florence Loyer
+ 33 (0)1 44 71 00 12 // + 33 (0)6 88 20 35 59
afloyer@newcap.fr
Lupus Europe
secretariat@lupus-europe.org
Neovacs (EU:ALNEV)
Historical Stock Chart
From Jun 2024 to Jul 2024
Neovacs (EU:ALNEV)
Historical Stock Chart
From Jul 2023 to Jul 2024